Sickle Cell Puts Black Patients at Higher Risk for Severe COVID-19 1490wosh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 1490wosh.com Daily Mail and Mail on Sunday newspapers.
Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH
DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7
th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy.
CoIMMUNE: Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH
DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy by principal investigator Andrea Biondi, M.D. and at Papa Giovanni XXIII, Bergamo, Italy by principal investigator Alessandro Rambaldi, M.D. The presentation on was on December 7
th during the immunotherapy session and was given by Dr. Chiara Magnani of the Tettamanti Research Center, Monza, Italy.
Dive Brief:
Regeneron has temporarily stopped enrolling new patients into trials of its experimental cancer drug odronextamab amid safety concerns raised by the Food and Drug Administration.
The FDA put a partial clinical hold on the development program and asked Regeneron to revise its trial protocols to better control cases of cytokine release syndrome, a known side effect of cancer cell therapies in which the immune system overreacts and begins attacking the body.
In a statement, Regeneron said it aims to resume patient enrollment in the first quarter of next year after submitting a revised trial plan to the FDA. The treatment is an important part of plans by Regeneron, best known for the eye drug Eylea, to become a major player in oncology.
Dec 15, 2020 at 7:03AM
CRISPR which stands for clustered regularly interspaced short palindromic repeats has been a hot area of research and investment since scientists discovered that this naturally occurring gene-editing function of bacteria could conceivably be used to treat genetic diseases. Several companies are using gene-editing in their attempts to cure illnesses caused by errors on a single gene such as sickle cell disease, hemophilia, and cystic fibrosis. One of them,
CRISPR
Therapeutics (NASDAQ:CRSP), has produced results that could not only make it a winner in single-gene disorders, but position it to tackle much more complex and profitable diseases in the years ahead.